Fighting poor quality health products in times of Covid-19 and beyond: the need for a multi-stakeholder approach
World Health Organization (WHO) estimates from 2017 indicates that 10.5% of medical products available in low- and middle-income countries (LMICs) are “substandard or falsified” (SF). Substandard health products are approved by the national regulators, but they do not comply with adequate standards due to undetected errors, negligence, or poor practice in manufacturing, transportation, or storage. This, in some cases, may be linked to corruption. Find out more here.